Spots Global Cancer Trial Database for transformed lymphoma
Every month we try and update this database with for transformed lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | NCT05256641 | Diffuse Large B... High-grade B-ce... Transformed Lym... Secondary Centr... | Acalabrutinib | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | NCT04058470 | Diffuse Large B... High-grade B-ce... Follicular Lymp... Transformed Lym... EBV-Positive DL... ALK-Positive An... | Toripalimab, Ri... R-CHOP Protocol | 60 Years - 75 Years | Sun Yat-sen University | |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | NCT04476459 | Diffuse Large B... High-grade B-ce... Follicular Lymp... Transformed Lym... EBV-Positive DL... ALK-Positive An... | Camrelizumab Apatinib | 18 Years - 80 Years | Sun Yat-sen University | |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | NCT02343536 | Lymphoma, Large... Lymphoma, Folli... | Oral Azacitidin... Rituximab cyclophosphamid... Vincristine Prednisone | 18 Years - | Celgene | |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | NCT04545762 | Refractory Non-... Burkitt Lymphom... Mantle Cell Lym... Follicular Lymp... Lymphoplasmacyt... Primary Mediast... Diffuse Large B... Small Lymphocyt... Transformed Lym... | Fludarabine Cyclophosphamid... anti-CD19 CAR-T... | 18 Years - | University of California, San Francisco | |
| Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes | NCT04319237 | Diffuse Large B... Transformed Lym... | Handgrip streng... Neuropsychologi... Neuropsychologi... Neuropsychologi... Neuropsychologi... Patient Reporte... European Organi... Quality of Life... PROMIS Cognitiv... Comprehensive S... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | NCT02343536 | Lymphoma, Large... Lymphoma, Folli... | Oral Azacitidin... Rituximab cyclophosphamid... Vincristine Prednisone | 18 Years - | Celgene | |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | NCT05281809 | B-Cell Lymphoma B Acute Lymphob... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Lymphoplasmacyt... Chronic Lymphoc... Transformed Lym... | Chimeric Antige... | 18 Years - 79 Years | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | NCT04476459 | Diffuse Large B... High-grade B-ce... Follicular Lymp... Transformed Lym... EBV-Positive DL... ALK-Positive An... | Camrelizumab Apatinib | 18 Years - 80 Years | Sun Yat-sen University | |
| DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | NCT03837873 | Diffuse Large B... High-grade B-ce... Transformed Lym... | Rituximab Etoposide Vincristine Doxorubicin Dexamethasone Cyclophosphamid... Lenalidomide Cisplatin Cytarabine | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
